Literature DB >> 1419647

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.

B Fiorentino1, P Di Stefano, C Giuliani, C Amatetti, N Tinari, C Natoli, C Garufi, S Iacobelli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1419647      PMCID： PMC1977987          DOI： 10.1038/bjc.1992.396

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  19 in total

Review 1.  Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S A Rosenberg
Journal:  Important Adv Oncol       Date:  1986

Review 2.  Interferons in host defense.

Authors:  C R Faltynek; J J Oppenheim
Journal:  J Natl Cancer Inst       Date:  1988-04-06       Impact factor: 13.506

Review 3.  Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.

Authors:  J Atzpodien; H Kirchner
Journal:  Klin Wochenschr       Date:  1990-01-04

4.  Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.

Authors:  R P Whitehead; D Ward; L Hemingway; G P Hemstreet; E Bradley; M Konrad
Journal:  Cancer Res       Date:  1990-10-15       Impact factor: 12.701

5.  Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A in cancer patients: a phase I study.

Authors:  K H Lee; M Talpaz; J M Rothberg; J L Murray; N Papadopoulos; C Plager; R Benjamin; D Levitt; J Gutterman
Journal:  J Clin Oncol       Date:  1989-11       Impact factor: 44.544

Review 6.  NIH conference. New approaches to the immunotherapy of cancer using interleukin-2.

Authors:  S A Rosenberg; M T Lotze; J J Mulé
Journal:  Ann Intern Med       Date:  1988-06       Impact factor: 25.391

7.  The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

Authors:  N S Rosenthal; J A Hank; P C Kohler; D Z Minkoff; K H Moore; R Bechhofer; R Hong; B Storer; P M Sondel
Journal:  J Biol Response Mod       Date:  1988-04

8.  In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Authors:  J A Hank; P C Kohler; G Weil-Hillman; N Rosenthal; K H Moore; B Storer; D Minkoff; J Bradshaw; R Bechhofer; P M Sondel
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

9.  Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.

Authors:  J Atzpodien; A Körfer; C R Franks; H Poliwoda; H Kirchner
Journal:  Lancet       Date:  1990-06-23       Impact factor: 79.321

10.  The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected].

Authors:  R C Stein; V Malkovska; S Morgan; A Galazka; C Aniszewski; S E Roy; R J Shearer; R A Marsden; D Bevan; E C Gordon-Smith
Journal:  Br J Cancer       Date:  1991-02       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.